Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

A new study shows that oxytocin nasal spray helps mothers with postpartum depression interact more positively with their babies.

People with hay fever could one day benefit from a first-of-its-kind “molecular shield” that blocks pollen from entering the ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Researchers at Radboud University and the Radboudumc found that mothers with postpartum depression benefit from oxytocin ...

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

MomMed, a trusted maternal and family wellness brand, today announced a strategic partnership with nasal care innovator ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...

ARS Pharmaceuticals' Neffy, an epinephrine nasal spray, is poised as a game-changer for emergency allergies, driving growth.